180 related articles for article (PubMed ID: 27109100)
1. Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells.
Shou P; Chen Q; Jiang J; Xu C; Zhang J; Zheng C; Jiang M; Velletri T; Cao W; Huang Y; Yang Q; Han X; Zhang L; Wei L; Rabson AB; Chin YE; Wang Y; Shi Y
Oncogene; 2016 Nov; 35(46):5953-5962. PubMed ID: 27109100
[TBL] [Abstract][Full Text] [Related]
2. TGF-β promotes immune responses in the presence of mesenchymal stem cells.
Xu C; Yu P; Han X; Du L; Gan J; Wang Y; Shi Y
J Immunol; 2014 Jan; 192(1):103-9. PubMed ID: 24293629
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo.
Xu C; Lin L; Cao G; Chen Q; Shou P; Huang Y; Han Y; Wang Y; Shi Y
Oncogene; 2014 Oct; 33(42):5047-52. PubMed ID: 24186200
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide.
Ren G; Zhang L; Zhao X; Xu G; Zhang Y; Roberts AI; Zhao RC; Shi Y
Cell Stem Cell; 2008 Feb; 2(2):141-50. PubMed ID: 18371435
[TBL] [Abstract][Full Text] [Related]
5. PPARβ/δ directs the therapeutic potential of mesenchymal stem cells in arthritis.
Luz-Crawford P; Ipseiz N; Espinosa-Carrasco G; Caicedo A; Tejedor G; Toupet K; Loriau J; Scholtysek C; Stoll C; Khoury M; Noël D; Jorgensen C; Krönke G; Djouad F
Ann Rheum Dis; 2016 Dec; 75(12):2166-2174. PubMed ID: 26964143
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal acid lipase in mesenchymal stem cell stimulation of tumor growth and metastasis.
Zhao T; Yan C; Du H
Oncotarget; 2016 Sep; 7(38):61121-61135. PubMed ID: 27531897
[TBL] [Abstract][Full Text] [Related]
7. Cumulus cell-expressed type I interferons induce cumulus expansion in mice.
Jang YJ; Park JI; Moon WJ; Dam PT; Cho MK; Chun SY
Biol Reprod; 2015 Jan; 92(1):20. PubMed ID: 25429090
[TBL] [Abstract][Full Text] [Related]
8. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
Schaber JD; Fang H; Xu J; Grimley PM; Rui H
Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
[TBL] [Abstract][Full Text] [Related]
9. Genetically engineered mesenchymal stromal cells producing TNFα have tumour suppressing effect on human melanoma xenograft.
Tyciakova S; Matuskova M; Bohovic R; Polakova K; Toro L; Skolekova S; Kucerova L
J Gene Med; 2015; 17(1-2):54-67. PubMed ID: 25677845
[TBL] [Abstract][Full Text] [Related]
10. STAT5 contributes to interferon resistance of melanoma cells.
Wellbrock C; Weisser C; Hassel JC; Fischer P; Becker J; Vetter CS; Behrmann I; Kortylewski M; Heinrich PC; Schartl M
Curr Biol; 2005 Sep; 15(18):1629-39. PubMed ID: 16169484
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cells inhibit CD25 expression via the mTOR pathway to potentiate T-cell suppression.
Yoo HS; Lee K; Na K; Zhang YX; Lim HJ; Yi T; Song SU; Jeon MS
Cell Death Dis; 2017 Feb; 8(2):e2632. PubMed ID: 28230853
[TBL] [Abstract][Full Text] [Related]
12. IFNα converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets.
Bachmann M; Ulziibat S; Härdle L; Pfeilschifter J; Mühl H
Biochem Pharmacol; 2013 Feb; 85(3):396-403. PubMed ID: 23153456
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cells: a double-edged sword in regulating immune responses.
Li W; Ren G; Huang Y; Su J; Han Y; Li J; Chen X; Cao K; Chen Q; Shou P; Zhang L; Yuan ZR; Roberts AI; Shi S; Le AD; Shi Y
Cell Death Differ; 2012 Sep; 19(9):1505-13. PubMed ID: 22421969
[TBL] [Abstract][Full Text] [Related]
14. Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects.
Jia XH; Feng GW; Wang ZL; Du Y; Shen C; Hui H; Peng D; Li ZJ; Kong DL; Tian J
Oncotarget; 2016 Apr; 7(15):20934-44. PubMed ID: 26988913
[TBL] [Abstract][Full Text] [Related]
15. Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.
Zhang JM; Feng FE; Wang QM; Zhu XL; Fu HX; Xu LP; Liu KY; Huang XJ; Zhang XH
Stem Cells Transl Med; 2016 Dec; 5(12):1631-1643. PubMed ID: 27471307
[TBL] [Abstract][Full Text] [Related]
16. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN.
Lee HJ; Oh YK; Rhee M; Lim JY; Hwang JY; Park YS; Kwon Y; Choi KH; Jo I; Park SI; Gao B; Kim WH
J Mol Biol; 2007 Jun; 369(4):967-84. PubMed ID: 17475277
[TBL] [Abstract][Full Text] [Related]
17. The deubiquitinating enzyme UCHL1 negatively regulates the immunosuppressive capacity and survival of multipotent mesenchymal stromal cells.
Gu Y; Ding X; Huang J; Xue M; Zhang J; Wang Q; Yu H; Wang Y; Zhao F; Wang H; Jin M; Wu Y; Zhang Y
Cell Death Dis; 2018 May; 9(5):459. PubMed ID: 29686406
[TBL] [Abstract][Full Text] [Related]
18. NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Xu P; Ye S; Li K; Huang M; Wang Q; Zeng S; Chen X; Gao W; Chen J; Zhang Q; Zhong Z; Lin Y; Rong Z; Xu Y; Hao B; Peng A; Ouyang M; Liu Q
J Exp Clin Cancer Res; 2019 Dec; 38(1):483. PubMed ID: 31805977
[TBL] [Abstract][Full Text] [Related]
19. Galectin-1 is a local but not systemic immunomodulatory factor in mesenchymal stromal cells.
Fajka-Boja R; Urbán VS; Szebeni GJ; Czibula Á; Blaskó A; Kriston-Pál É; Makra I; Hornung Á; Szabó E; Uher F; Than NG; Monostori É
Cytotherapy; 2016 Mar; 18(3):360-70. PubMed ID: 26857229
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
